Company: RCUS
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0001724521-25-000052
Chunk: 47

Company: Arcus Biosciences, Inc.
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 47
---
 responsibilities. We believe this balances against the impact of having the remainder of their compensation at risk in the form of annual cash bonuses and equity-based incentive compensation. The Compensation Committee establishes base salary amounts based on a number of factors, including the scope of the executive officer’s responsibilities, experience, achievements, leadership, teamwork and value to us, and the committee's review of market data from peer companies provided by our compensation consultant, Radford. The Compensation Committee reviews the base salary of each of our executive officers on at least an annual basis and may make discretionary adjustments from time to time.

For 2024, Dr. Rosen received a base salary of $725,000 (an increase of $75,000 from the prior year), Mr. Goeltz received a base salary of $510,000 (an increase of $20,000 from the prior year), Dr. Jaen received $625,000 (an increase of $50,000 from the prior year), Ms. Jarrett received $625,000 (an increase of $50,000 from the prior year) and Dr. Nuyten received $585,000 (an increase of $23,000 from the prior year).

Cash Bonus

Cash bonus is intended to motivate and reward our executive officers for attaining rigorous annual corporate performance goals that relate to our key business objectives. The Compensation Committee generally reviews annually the target bonus amounts, calculated as a percentage of base salary, which are determined based on the scope of the executive officer’s responsibilities, experience, achievements, leadership, teamwork and value to us and after referencing market data

<div align='center'>26.</div>

from peer companies provided by our compensation consultant, Radford, generally referencing the 50th to 75th percentile. The Compensation Committee determines actual bonus amounts earned after the end of the year based on our overall performance and each individual’s achievement and contributions.

Our annual corporate performance goals are typically established around the beginning of each year. Management prepares a set of goals covering corporate, development and financial objectives and key activities, which is then reviewed and, following any modification the Compensation Committee deems appropriate, approved by our Compensation Committee. For 2024, our Compensation Committee approved corporate performance goals, which included:

• maintaining timelines associated with our Phase 3 studies STAR-121 and STAR-221;

• initiating a Phase 3 study for quemliclustat in pancreatic cancer;

• generating data supportive of our development plans for casdatifan;

• advancing our early-stage clinical portfolio, which includes AB801 and